---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-025524"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:11:55.683647+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Agios board member David Schenkein resigns effective Feb 28, 2025; stays as strategic advisor

## Summary
- Dr. Schenkein notified company of resignation from board on Feb 10, 2025, effective Feb 28, 2025.
- He will also cease serving on the Science and Technology Committee of the board.
- He will continue as a strategic advisor to leadership, focusing on advancing clinical development programs.

## SEC filing metadata
- accession: 0001193125-25-025524
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312525025524/0001193125-25-025524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312525025524/d927492d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-025524
- JSON: https://secwatch.observer/filing/0001193125-25-025524.json
- Plain text: https://secwatch.observer/filing/0001193125-25-025524.txt

## Key facts
- Executive change
  David P. Schenkein, M.D. resigned as Director at AGIOS PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Director
  source text: On February 10, 2025, David P. Schenkein, M.D., notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective February 28, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312525025524/0001193125-25-025524-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.